real world data

Real-world data collected from a registry can be used to reliably compare the effectiveness of different multiple sclerosis (MS) treatments, so long as appropriate methodologies are employed to account for the messiness — what researchers call confounding bias — of real-world data, according to a new study. While registries…

Treatment with Ocrevus (ocrelizumab) may stabilize disability progression in people with multiple sclerosis (MS) who have severe walking impairments — a patient group excluded from clinical trials supporting the therapy’s 2017 approval — a real-world analysis suggests. However, about half of those receiving Ocrevus in this study discontinued…

Among multiple sclerosis (MS) patients treated with Ocrevus (ocrelizumab), most of the disability worsening they experience is not associated with any relapse activity, according to an analysis of real-world data. “We present real-world data from our multiple sclerosis center underlining that in a typical population of relapsing MS…

Real-world use of nabiximols, an oral spray cannabinoid treatment, was associated with a self-reported easing of spasticity and related symptoms for people with multiple sclerosis (MS), according to a recent study in Austria. Most patients (87.5%) said they were at least partly satisfied with the therapy — available…

Treatment with Gilenya (fingolimod) for up to four years was found safe and lowered relapse rates among people with multiple sclerosis (MS) in the Czech Republic, according to a real-world study called GOLEMS. Older age, lower disability level, and fewer relapses prior to the treatment’s start were all…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Mavenclad…

In its work on multiple sclerosis (MS), Biogen has adopted a comprehensive approach that ranges from  drug development to the exploration of real-world data and digital markers of disease. The company will showcase these efforts at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris on October 25–28. Among its more than 80 presentations at the meeting are updates from its collaboration with Verily and Brigham and Women’s Hospital on using digital sensors that gather data on MS patients between physician visits. Biogen will also share data on the possibility of using such biomarkers to help neurologists in diagnosing and following MS patients — offering information that could potentially help them in making treatment decisions given the variability of the disease in MS patients. The company is also involved in a collaboration with 10 MS centers that aims to generate data collected during routine care. The MS PATHS study includes data from physical examinations, magnetic resonance imaging (MRI) scans, and biological samples. A third and similar project — the Big Multiple Sclerosis Data (BMSD) Network —  is merging data from five MS registries, holding prospective information on nearly 140,000 patients. Taken together, these large collections of high-quality, real-world data will help researchers better understand the disease, and so, increase the potential of new treatment discoveries, Biogen says. The company is also working to discover and develop biomarkers that are not digital that may also advance the understanding of MS and its treatment. One such marker is neurofilament light, which signals damage to neuronal axons. Biogen will share data on how this marker changes over time in MS patients. Among presentations focusing on treatment development, Biogen will highlight new efforts with opicinumab . The treatment — intended to repair damage by triggering remyelination — failed to reach it primary goal in the Phase 2 SYNERGY trial earlier this year. Still,  data indicated that some trial participants did respond to the treatment. At ECTRIMS, Biogen will present an analysis of the SYNERGY data that identifies factors — including specific MRI features — that may be linked to a treatment response.  

GNS Healthcare is presenting a data-driven causal machine learning solution, called Efficacy to Effectiveness, designed to predict how potential therapies will actually perform in distinct populations. The data, being released today at ISPOR 2016, used pre-launch data from a study comparing Gilenya (fingolimod) and other multiple sclerosis (MS) therapies to build and validate causal models…